Please assess the completion status of the following clinical trial:

Trial Title: Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Males and females aged 18 years or more are eligible for the study if they meet all the following inclusion criteria:~* New diagnosis of PV according to WHO 2007 diagnostic criteria including Jak 2 V617F mutation status;~* Old diagnosis of PV confirmed with JAK-2 positivity and clinical course of the disease;~* Ability and willingness to comply with all study requirements;~* Written informed consent (obtained before any study specific procedure).~Exclusion Criteria:~* Pregnant or lactating women or women of childbearing potential who are not protected from pregnancy by an accepted method of contraception;~* Known hypersensitivity or contraindication to study treatments;~* Significant liver (AST or ALT \> 2.5 times ULN) or renal disease (creatinine \> 2 mg/ml);~* Presence of any life-threatening condition or of any disease (e.g. cancer) that is likely to significantly shorten life expectancy;~* History of active substance or alcohol abuse within the last year;~* Any condition that in the opinion of the investigator would jeopardize the evaluation of efficacy or safety or be associated with poor adherence to the protocol - Baseline and FUP visits schedule and assessments~* Logistic problem related to the patient.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cytoreduction for HCT < 45% (Type: ACTIVE_COMPARATOR): Patients will be treated with phlebotomy and/or HU more intensively, with the goal to reach and maintain the target of hematocrit(HCT)below 45%. Phlebotomy should be performed initially by removing 250-500 ml of every other day or twice a week until the target HCT is obtained. Hydroxyurea (HU)should be administered initially at a dose of 0.5-1.0 g daily. Blood counts at regular intervals (monthly) will establish the frequency of future phlebotomies with the goal to maintain the target HCT. Supplemental iron therapy should not be given. Low-dose aspirin is the standard antithrombotic therapy in PV and will be administered to all patients with no contraindications to aspirin.
- Cytoreduction for HCT between 45 and 50% (Type: EXPERIMENTAL): Patients will be treated with phlebotomy and/or HU less intensively, with the goal to reach and maintain the target of hematocrit(HCT)between 45% and 50%. Phlebotomy should be performed initially by removing 250-500 ml of every other day or twice a week until the target HCT is obtained. Hydroxyurea (HU)should be administered initially at a dose of 0.5-1.0 g daily. Blood counts at regular intervals (monthly) will establish the frequency of future phlebotomies with the goal to maintain the target HCT. Supplemental iron therapy should not be given. Low-dose aspirin is the standard antithrombotic therapy in PV and will be administered to all patients with no contraindications to aspirin.

Based on this trial design, predict the completion outcome and termination type (if applicable).